Friday, 18 Oct 2019

You are here

Fresolimumab (anti-TGF beta) Improves Systemic Sclerosis

Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments. The role of TGF-β in SSc, was put to the test in a trial of 15 SSc patients (with a mean disease duration of 8 months) who were treated with 2 different dosing regimens of fresolimumab (an IgG4 κ monoclonal antibody capable of neutralizing TGF-β).  

Patients received either two doses of 1 mg/kg 4 weeks apart (n=7) or one 5 mg/kg dose (n=8) and were assessed at baseline, weeks 3 or 4, 7, and 24 weeks with modified Rodnan skin scores (mRSS), serial skin biopsies, biomarkers and microarrays.  Among the 11 females and 4 males, 60% had digital ulcers, 93% were ANA+, 27% were SCL-70 Ab positive and they had a mean mRSS of 26.9. Only one patient had pulmonary fibrosis.

Rice and coworkers reported that nearly all patients showed a rapid, significant decrease in skin scores, Expression of the biomarkers thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) rapidly declined at one month and week 7. Skin scores began to reverse after week 11 but COMP and THBS1 expression lagged behind, suggesting repeat dosing may be needed in the future.  

Nevertheless, strong correlations were seen between biopsy site (forearm) scores, mRSS, COMP and THBS1.  When compared to other trials, the degree and rapidity of mRSS improvement suggest these changes were more than the natural regression of skin scores in SSc. This this open-label pilot trial, using a first in class inhibitor of TGF-β, has shown significant clinical and biologic effects in patients with diffuse scleroderma.

Thanks to Dr. Barry Gruber of Long Island for identifying this citation.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.